You just read:

Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study

News provided by

Convergence Pharmaceuticals

16 Jun, 2014, 07:00 BST